ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0288

Physician Attitudes Toward Diagnosis, Treatment Initiation, and Unmet Needs in the Management of Anemia due to CKD: Results from a Real-World Survey in Germany, Italy, and the United Kingdom

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism

Authors

  • Kabra, Madhusudan, Otsuka Pharmaceutical Europe Limited, Slough, United Kingdom
  • Hammond, Tim, Otsuka Pharmaceutical Europe Limited, Slough, United Kingdom
  • Fleetwood, Allison, Otsuka Pharmaceutical Europe Limited, Slough, United Kingdom
  • Harrison, Lewis, Adelphi Real World, Bollington, Cheshire, United Kingdom
  • Jackson, James, Adelphi Real World, Bollington, Cheshire, United Kingdom
  • Clayton, Sarah, Adelphi Real World, Bollington, Cheshire, United Kingdom
Background

Anemia, a complication of chronic kidney disease (CKD), is often defined as serum hemoglobin (Hb) levels of <12 g/dL in women and <13 g/dL in men. Traditionally, primary care physicians (PCPs) have less involvement managing and treating patients with anemia due to CKD while nephrologists play a greater role in treatment decisions. We describe current physician perceptions towards the diagnosis and treatment of anemia due to CKD and unmet needs in anemia management, in a real-world setting.

Methods

Data were drawn from the Adelphi CKD Disease Specific Programme, a point-in-time study conducted between November 2019 and April 2020 with nephrologists and PCPs from Germany, Italy and the United Kingdom. Physicians completed an online survey providing information on their demographics, opinions on the diagnosis and treatment of anemia, and the current unmet needs they believe exist in the management and treatment of anemia. Results were descriptively analyzed.

Results

A total of 200 physicians (n=140 nephrologists; n=60 PCPs) were included in the analysis. Among those who responded, the majority (98% nephrologists; 80% PCPs) used Hb levels to diagnose anemia in CKD patients. Over two thirds of physicians mentioned using ferritin to diagnose anemia and over half reported using transferrin saturation (TSAT) levels.

Approximately 4 in 5 nephrologists and PCPs (78% nephrologists; 81% PCPs) reported Hb levels to be the most important factor that triggers initiation of anemia treatment in CKD patients.

The top unmet needs in the management and treatment of CKD anemia reported by both nephrologists and PCPs were treatment for refractory/resistant patients (37% nephrologists; 40% PCPs) and the need for more oral treatments (31% nephrologists; 37% PCPs).

Conclusion

These data reinforce that Hb levels, ahead of ferritin and TSAT levels, have an important role in the diagnosis and initial prescription of therapy for anemia in CKD patients. It also highlights an unmet need for treatment of refractory/resistant patients and the desire among nephrologists and PCPs for more alternative modes of administration to treat anemia due to CKD.

Funding

  • Commercial Support